Skip to main content Skip to section navigation Skip to footer
Kazia Therapeutics Corporate homepage
  • About Us
    • Company Overview
    • Management
    • Board of Directors
  • Pipeline
    • Pipeline Overview
    • Paxalisib
    • PD-L1 Protein Degrader
    • SETDB1 Inhibitor
    • EVT801
    • Clinical Trials
    • Posters & Publications
  • Technology
  • Media Center
    • Media Center Overview
    • News
    • Events
    • In The News
    • Video Gallery
    • ASX Announcements
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
    • ASX Delisting
  • Contact Us

In The News

Media Center

  • Media Center Overview
  • News
  • Events
  • In The News
  • Video Gallery
  • ASX Announcements
Jul 2, 2026 Kazia Therapeutics Discusses Shift for Paxalisib Into Triple-Negative Breast Cancer
May 29, 2026 Base to Base biotech podcast 61: Making tumours visible, and taking on tough challenges
Feb 11, 2025 QIMR Berghofer Podcast: World first clinical trial to test new approach to target triple negative breast cancer
Jan 30, 2025 Skynews: Breakthrough research by QIMR with Kazia Therapeutics to develop breast cancer drug
Dec 2, 2024 BioSpace: Biopharma Takes on Deadly Brain Cancer After Decades of Failure
May 2, 2024 Kazia reports successful stage 1 completion of the EVT801 Phase 1 clinical trial in advanced cancer patients
Feb 11, 2024 Professor takes big step in fighting cancer which claimed his daughter
Dec 23, 2023 Parents of kids with DIPG say funding for trial urgently needed
Nov 23, 2023 Kazia provides overview of Paxalisib related presentations from the Society of Neuro-Oncology 2023 Annual Meeting
May 1, 2023 Kazia Therapeutics appoints Dr John Friend as new CEO
rss_feed RSS
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Next Pagearrow_forward
©2026 Kazia Therapeutics. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement